Adds emphasis on including the ACC/AHA stage 1 HBP population and combines both ACC/AHA stage 2 and stage 1 HBP populations. PM-4 Nonpharmacological interventions for ACC/AHA stage 2 HBP Physician group practice, accountable care organization, clinically integrated network, health plan, integrated delivery system Harmonizes with current performance measure Controlling High Blood Pressure for ACC/ AHA stage 2 HBP currently in widespread use. Adds new emphasis on high-quality evidence and strong recommendation for promoting lifestyle modification, as recommended in the 2017 Hypertension Clinical Practice Guidelines for this population as an important strategy for controlling HBP. PM-5 Use of HBPM for management of ACC/AHA stage 2 HBP Healthcare provider (healthcare provider, physician group practice, accountable care organization, clinically integrated network, health plan, integrated delivery system) Harmonizes with current performance measure Controlling High Blood Pressure for ACC/ AHA stage 2 HBP currently in widespread use. Adds new emphasis on correct measurement of BP by individuals at home or elsewhere outside the clinic setting, as recommended in the 2017 Hypertension Clinical Practice Guidelines for this population as an important strategy for evaluating control of HBP. QM-1 Nonpharmacological interventions for ACC/AHA stage elevated BP Physician group practice, accountable care organization, clinically integrated network, health plan, integrated delivery system Adds new emphasis on high-quality evidence and strong recommendation for promoting lifestyle modification, as recommended in the 2017 Hypertension Clinical Practice Guidelines for ACC/ AHA elevated BP population as an important strategy for controlling HBP. QM-2 Nonpharmacological interventions for ACC/AHA stage 1 HBP Physician group practice, accountable care organization, clinically integrated network, health plan, integrated delivery system Adds new emphasis high-quality evidence and strong recommendation for promoting lifestyle modification, as recommended in the 2017 Hypertension Clinical Practice Guidelines for ACC/ AHA stage 1 population as an important strategy for controlling HBP. 